All In Biotech

Investigational drug · Phase 2

matching dosage

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Weight Management, Overweight , Obesity, Overweight and/or Obesity.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

8,288

Any phase or sponsor naming "matching dosage"

First trial start

2025

Nov 18, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "matching dosage", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Weight Management
  • Overweight , Obesity
  • Overweight and/or Obesity

Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "matching dosage" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Weight Management

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • EcnoglutideXW003, VRB-101Phase 38 trials

    Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea

  • ECC4703Phase 22 trials

    Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis

  • GV101Phase 22 trials

    Graviton Bioscience Corporation · Friedreich's Ataxia, Weight Management

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.